CME
What Is the Latest Real-World Evidence With CDK4/6 Inhibitors in Metastatic HR+ Breast Cancer?
February 10, 2023
Guest: Hope S. Rugo, MD, FASCO The introduction of cyclin-dependent kinase (CDK) 4/6 inhibitors has drastically changed the treatment landscape of hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) metastatic
Visit Podcast Website
RSS Podcast Feed
Subscribe
Share
Add to MyCast
Gain access to Blubrry tools that help build your podcast, including free podcast stats!